»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ of?'FrU
f#zm}+,`
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨»ù´¡¿Î£©¿ÆÄ¿´úÂ룺806 #N `Z)}Jm
!;;WS~no3
Ò»Ãû´Ê½âÊÍ£¨¹²5Ì⣬ÿÌâ4·Ö£¬¹²20·Ö£© p*"H&xA@
1.Antigen presenting cell£¨APC£© eEMU,zCl
2.Activation induced cell death£¨AICD£© *9xv0hRQ%?
3.Chemokine 5$L=l
4.Major histocompatibility complex£¨MHC£© K
cNh3CR
5.immunotolerance ,xsFBNCC
!
[4<6/2gy
¶þÎÊ´ðÌ⣨¹²5Ì⣬ÿÌâ10·Ö£¬¹²50·Ö£© 0'4V*Y
1.ÊÔÊö²ÎÓëThϸ°ûÓëBϸ°ûÏ໥¼¤»îµÄ·Ö×Ó¼°¸÷×ԵŦÄÜ 7Q3a0`Iq
2.ºÎν𤸽·Ö×Ó£¿¼òÊö𤸽·Ö×ӵķÖÀ༰ÆäÔÚÃâÒßÖеÄ×÷Óà tgB\;nbB
3.¼òÊöIIÐͳ¬Ãô·´Ó¦µÄ·¢Éú»úÖÆ ;UG]ckV-
4.ÔÚÕý³£Çé¿öÏ£¬ÃâÒßϵͳ¶Ô×ÔÉí¿¹Ô²»²úÉúÃâÒßÓ¦´ðµÄ»úÖÆÊÇʲô£¿ COk;z.Kn
5.±È½ÏCTLºÍNKɱÉË°Ðϸ°ûʱʶ±ðºÍɱÉË»úÖƵÄÌصã eW^_YG%(
ts3BmfR?
ÈýÑ¡´ðÌ⣨µÚ1Ìâ±Ø´ð£¬2ºÍ3ÌâÈÎÑ¡1Ì⣬ÿÌâ15·Ö£¬¹²30·Ö£© XF 8$D
1.¼òÊöÒÆÖ²ÅųⷴӦÖÐÊÜÕßTϸ°û¶ÔͬÖÖÒìÌ忹ԵÄʶ±ð»úÖÆ¡£Í¨¹ýÖ±½Óʶ±ð¼¤»îµÄÊÜÕßThϸ°ûºÍTcϸ°û·Ö±ðÔÚ¸¨ÖúÊÜÕßBϸ°ûºÍɱÉËÒÆÖ²Îï·½ÃæÓë¼ä½Óʶ±ð¼¤»îµÄThºÍTcÓкβîÒ죿Ϊʲô£¿ KM;'MlO
2.½áºÏÄãµÄרҵÊÔÊöϸ°ûÒò×ÓÔÚ¼²²¡·¢Éú·¢Õ¹ÖеÄ×÷Óã¬Ä㽫²ÉÈ¡ÄÄЩ²ßÂÔÕë¶ÔÕâЩ°ÐµãÖÎÁƼ²²¡£¿ 8rx"D`{|
3.ºÎΪ»ùÒò¹¤³Ì¿¹Ì壿Ŀǰ¹úÄÚÍâÔÚ»ùÒò¹¤³Ì¿¹ÌåÑо¿ÖÐÓÐÄÄЩÖ÷Òª½øÕ¹£¿ `$odxo+
Ysz&/
ry
»ªÖпƼ¼´óѧͬ¼ÃҽѧԺ2003Äê¹¥¶Á²©Ê¿Ñ§Î»Ñо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ /?wH1 ,
PA(XdT{
¿¼ÊÔ¿ÆÄ¿£ºÒ½Ñ§ÃâÒßѧ£¨×¨Òµ¿Î£©¿ÆÄ¿´úÂ룺906 {2Jn#&Z29
RiX~YLeM
Ò»Ãû´Ê½âÊÍ£¨4·Ö/Ì⣩ g:sn/Zug]
1.Antigenic determinant `pzXh0}|
2.IgSF |3A/Og
3.MBL;¾¶ ub0uxvz
4.chemokine *$I5_A8,.
5.HLA¸´ºÏÌåµÄ¶à»ùÒòÐÔÓë¶àëÄÐÔ XH?}0D(
6.TCR-CD3¸´ºÏÎï (79y!&9p
7.FADD£¨Fas-associated protein with death domain£© ?zD?-
8.AIDS 3.
kP,
9.Tumor rejection antigen >K2Md*[P3q
10.AICD K2u$1OKv
dDAIfe2y
¶þÎÊ´ðÌ⣨15·Ö/Ì⣩ 61W
ms@D%
1.¼òÊöCD·Ö×ÓÔÚÃâÒßЧӦÖеÄ×÷Ó㨰´ÊÜÌå·ÖÀà¼òÊö£© jJxV)AIY
2.¼òÊöBϸ°û²ÎÓëµÄÃâÒß¹¦ÄÜ #=G[~m\
3.¼òÊö×ÔÉíÃâÒßÐÔ¼²²¡Ê±Õë¶Ô×ÔÉí×éÖ¯²úÉúÃâÒßÓ¦´ðµÄ¿ÉÄÜ»úÖÆ b`=\<u8
4.ºÎνͬÖÖÒìÐÍMHC¿¹ÔÖ±½Óʶ±ðºÍ¼ä½Óʶ±ð£¿¼òÊöÆäÒì FOFZ/q
/"Bm1
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾Å¶þÄê¹¥¶Á˶ʿÑо¿ÉúÈëѧÊÔÌâ }T}9AQ}|
e*7nq~ B5
nnV(MB4z1
רҵ¿Î ÃâÒßѧ }w0>mA0=H
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê x>?jfN,e
1. Immunotoxin 2. T inducer 3. T cell receptor 4. Accessory cell ;<JyA3i^V,
5. Fc¦Å receptor 6. Cytokine H WOl79-
¶þ¡¢ ÎÊ´ðÌâ J;K-Pv+
1. ÃâÒßϵͳÖУ¬ÄÄЩϸ°ûÄÜÌØÒì»ò·ÇÌØÒâÐÔµØɱÉË°Ðϸ°û£¬ÊÔ·Ö±ð¼òÊöɱÉË×÷ÓõIJ»Í¬Ìص㡣 %V>Ss9;/8
2. ¸ù¾ÝT¡¢Bϸ°û±íÃæ±êÖ¾µÄ²»Í¬£¬¿ÉÒÔÓ¦ÓÃÄÄЩÃâÒßѧ¼¼Êõ¼ø±ðÕâÁ½Ààϸ°û£¬¼òÊöÓйصÄʵÑéÔÀí£¿ &B</^:
3. ÔÚIVÐͳ¬Ãô·´Ó¦ÖУ¬ÖÂÃôTϸ°ûÊÍ·ÅÄÄЩÁÜ°ÍÒò×Ó²ÎÓëÃâÒßËðÉË£¬ÏêÊöÆä×÷ÓûúÀí¡£ j{i3lGaN
4. ÊÔÊöHLA¸´ºÏÌåµÄÒÅ´«Ìص㼰ÕâЩÌصãµÄÉúÎïѧÒâÒ壿 MT8BP)C
5. ºÎνµ¥¿Ë¡¿¹Ì壿ÏêÊöÆäÔÚ»ù´¡ÓëÁÙ´²Ò½Ñ§ÖеÄÓ¦Óᣠkjo,?$r
%
hP=^JH
7r`A6 \
!
c~@
Z
7IrbwAGZ3
bZ-"R 6a$
ͬ¼ÃÒ½¿Æ´óѧһ¾Å¾ÅÈýÄê¹¥¶Á˶ʿѧλÑо¿ÉúÈëѧÊÔÌâ xQ[~ c1
i?.7o*w8
V
&K:~[ M
רҵ¿Î ÃâÒßѧ dM%#DN8l
Ò»¡¢ ·Òë²¢½âÊÍÏÂÁÐÃû´Ê 2S~cW./#fX
1¡¢ Complement receptor type ¢ñ 2¡¢ Serologically defined antigen f^P:eBgpx
3¡¢ Transfer factor 4¡¢ Immunotoxin 5¡¢ Perforin +d7sy0
6¡¢ Arthus reaction 7¡¢ Network theoty 8.Lymphocyte transformation test DrfOz#a0Uu
9. Hybridoma technic 10.Mitogen AY{-Hf&
11.Dentritic cell 12.Immunoproliferation }:5_vH0
¶þ¡¢ »Ø´ðÏÂÁÐÎÊÌâ wT;3>%Mtr
1¡¢ ÍÌÊÉϸ°û¶Ôϸ¾úµÄÍÌÊɹý³Ì°üÀ¨Äļ¸¸öÖ÷Òª½×¶Î£¬ÊÔÏêÊöÖ®¡£ RTPxAp+\5
2¡¢ ÊÔÊöIL-2µÄϸ°ûÀ´Ô´¹¦Äܼ°ÁÙ´²Ó¦Óᣠk<aKT?Ek>
3¡¢ Ò©Îï»ò»¯Ñ§ÊÔ¼ÁÒýÆðµÄÒ©ÕîÊôÓÚʲôÐͳ¬Ãô·´Ó¦£¬ÊÔÊöÆä»úÀí¡£ V'kCd4
4¡¢ ÌåÄÚµÄÃâÒß·Ö×Ó°üÀ¨Äļ¸ÀࣿÊÔ¼òÊö¸÷ÀàÃâÒß·Ö×ÓµÄÖ÷Òª¹¦ÄÜ¡£ &